On October 24, 2024, the Xinhuanet client published an article, “Domestic Ultrasonic Surgeon Technology Enters the “7mm” Era”, reporting on Wuhan Half the Sky’s 7mm Ultrasonic Surgeon.
The article clearly states that the scientific research achievement that domestic ultrasonic scalpel technology has entered the “7 mm” era was pioneered by Wuhan Half the Sky Medical Technology Development Co., Ltd. and has overall reached the international advanced level.
Within 8 hours of the article being online, it received nearly 1 million views. Currently, the number of views has exceeded one million and continues to increase.
China’s first 7mm radiofrequency ultrasonic scalpel made by Half the Sky
“7mm is a technical threshold, and domestic radiofrequency ultrasonic scalpel technology has been stagnant at 5mm for a long time.” In exchanges with clinicians from many hospitals in Wuhan, Qiu Xuewen, chairman of Wuhan Half the Sky, realized this clinical problem and was determined to develop a radiofrequency ultrasonic scalpel that can close blood vessels of 7 mm.
In order to increase the radio frequency energy while ensuring the stability of the ultrasound system, Wuhan Half the Sky Medical’s R&D team actively invested in redesigning the technical route, introducing conductive materials, adjusting frequency modes, integrating intelligent feedback systems, etc. After years of hard work, they successfully developed my country’s first 7 mm bipolar high-frequency ultrasound dual-output soft tissue surgical equipment in November 2023, and obtained the national Class III medical device registration certificate. In March 2024, the company obtained the second domestic registration certificate for a radiofrequency ultrasonic scalpel that can close blood vessels with a diameter of 7 mm. This is not only a breakthrough in the core technology of ultrasonic scalpel, but also has a significant effect on improving surgical efficiency and reducing risks.
The development of new qualitative productive forces in Wuhan Half the Sky not only focuses on “newness”, but also focuses on “quality”. After countless burst pressure experiments and animal tests, the radiofrequency ultrasonic knife produced by Wuhan Bantian has reduced the knife breakage rate from 1% to less than 0.5%. The scientific and technological achievements evaluation report issued by Hubei Technology Exchange shows that the scientific and technological achievements of this project have reached the international advanced level as a whole.
Domestic centralized procurement wins bids one after another and products are sold overseas
At present, Wuhan Half the Sky’s 7mm ultrasonic scalpel has obtained access qualifications for the domestic market and the EU market. In the domestic market, the radiofrequency ultrasonic scalpel developed by Wuhan Half the Sky has covered 30 provinces, regions, and cities across the country, and has been successfully used in more than 800 hospitals. It has won bids for centralized procurement in Guangdong 16 Province Alliance, Sichuan-Chongqing Alliance, Beijing-Tianjin-Hebei and other places. The latest data from the China Medical Device Industry Association shows that Wuhan Half the Sky Medical has a market share of 16.13% in the domestic radio frequency ultrasonic scalpel industry in 2023, and a market share of 58.37% in Hubei Province. It ranks first in the province’s industry sales and is a single product manufacturing champion enterprise in Hubei Province. After valuation by multiple investment institutions, the company’s market value exceeds 1 billion yuan.
In the international market, Half the Sky’s 7mm radiofrequency ultrasonic scalpel has obtained the EU CE certification. Qiu Xuewen said with confidence: “We have found partners in more than 20 countries. Last year, our foreign trade sales reached 30 million yuan. Our products are exported to the European Union, the United Kingdom, South America, Southeast Asia, India, Israel and other places. Our international market territory continues to expand.”
Based in China and looking at the world, Wuhan Half the Sky actively responds to the call for domestic substitution of high-end medical devices, and is committed to providing more efficient, comprehensive, and leading minimally invasive interventional treatment solutions for more specialties, and becoming an innovative, international, and comprehensive minimally invasive medical device leader!
